Starpharma Holdings |
High $0.31 |
Low $0.29 |
Trades 582 |
Turnover $291,413 |
Volume 965,700 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (14-Nov) $205,237,200 (436th) |
Close (30-Jun) $0.310 |
Volume (30-Jun) 965,700 |
Shortsold (9-Nov) 1,745,574 (0.36%) (353rd) |
|
52w High $0.88 |
52w Low $0.320 |
P/E 312.50 |
EPS -0.02 |
VIRALEZE antiviral nasal spray registered in Saudi Arabia
SPL released this announcement to the ASX on 14 December 2021, 9:55. The announcement is not marked as price sensitive, and is 2 page(s) in length and 238.22kb in size.
You can view all announcements from SPL and see how they appear on a price chart on the announcements page.
At the date of this announcement, SPL was 2.793% short sold according to ASIC data. It was ranked the 59th most shorted stock on the ASX. It remains ranked 353rd as of the latest reported data (09 November 2026).
| Other Recent Announcements from SPL | |
|---|---|
| Clinical Trial Update | 27 June 2023, 9:57 |
| Life Sciences Investor Forum Presentation | 23 June 2023, 10:42 |
| Starpharma to present at Life Sciences Investor Forum | 22 June 2023, 12:48 |
| VIRALEZE antiviral nasal spray registered in Saudi Arabia | 14 December 2021, 9:55 |
| VIRALEZE successfully launched in Vietnam | 13 December 2021, 11:04 |
| US Biopharma DEP Research Agreement - Additional Information | 8 December 2021, 10:06 |
| Starpharma signs DEP Research Agreement with US Biopharma Co | 7 December 2021, 9:08 |
If you were already registered, log in here.